NEWS

New Publication: Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

IQN Path is pleased to announce the first publication on Liquid Biopsy clinical implementation and quality assessment. Four EQA providers came together under the umbrella of IQN Path ASBL to run a pilot External Quality Assessment scheme for circulating free DNA. This publication “Review of the implementation of plasma ctDNA testing on behalf of IQN Path read more…

6th Meeting on External Quality Assessment in Molecular Pathology – Naples 2017

For the sixth consecutive year, representatives of the stakeholders involved in promoting accurate diagnostic testing in pathology for effective anti-cancer drug selection gathered in the second weekend of May 2017, in Naples, Italy. This very dynamic meeting always brings much discussion of the current key issues, and importantly, proposed solutions to optimising diagnostic testing quality read more…

Quality Assurance for Clinical Immunohistochemistry

IQN Path and the International Society for Immunohistochemistry and Molecular Morphology (ISIMM) have put together a 4-part series on Quality Assurance for Clinical Immunohistochemistry. “Evolution of Quality Assurance for Clinical Immunohistochemistry (IHC) in the Era of Precision Medicine” from the lead author Emina Torlakovic. –      Part 1: Fit-for-purpose Approach to Classification of Clinical IHC Biomarkers –      read more…

New Article in ESMO Open

In April this year, for the fifth consecutive year, representatives of all stakeholders involved in promoting accurate diagnostic testing for anticancer drug selection gathered in Naples in order to optimise the chance that patients will have an appropriate test which forms the basis for the decision of administering targeted treatment. The article published on ESMO read more…